Premium
P4‐424: NILVAD: An investigator initiated multi‐centre placebo‐controlled phase III trial of Nilvadipine, a calcium channel blocker, in mild‐to‐moderate Alzheimer's disease
Author(s) -
Lawlor Brian,
Crawford Fiona,
Rikkert Marcel Olde,
Mullan Michael,
Tsolaki Magda,
Borjesson Anne,
Pasquier Florence,
Riepe Matthias,
Kenny Rose Anne,
Howard Robert,
Gaynor Siobhan,
Molloy William
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.09.120
Subject(s) - placebo , calcium channel blocker , medicine , clinical trial , disease , psychological intervention , psychology , psychiatry , calcium , alternative medicine , pathology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom